{
  "ticker": "LLY",
  "entities": [
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 0,
      "end": 9,
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "context": "Eli Lilly and Company (LLY) shares moved today on a mix of",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 23,
      "end": 26,
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "context": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research,",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "today",
      "label": "DATE",
      "start": 41,
      "end": 46,
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "context": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, a",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "up to 300%",
      "label": "PERCENT",
      "start": 268,
      "end": 278,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Be",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 338,
      "end": 347,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "h from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive S",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "300%",
      "label": "PERCENT",
      "start": 371,
      "end": 375,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "reet Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lof",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "JPMorgan",
      "label": "ORG",
      "start": 407,
      "end": 415,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "s Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1,100",
      "label": "MONEY",
      "start": 429,
      "end": 434,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "a decade",
      "label": "DATE",
      "start": 484,
      "end": 492,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Li",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 536,
      "end": 545,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price T",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "JPMorgan",
      "label": "ORG",
      "start": 562,
      "end": 570,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1,100",
      "label": "MONEY",
      "start": 582,
      "end": 587,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "es.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive S",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Guggenheim",
      "label": "ORG",
      "start": 647,
      "end": 657,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "get and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "942",
      "label": "MONEY",
      "start": 689,
      "end": 692,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "timent:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "18.7%",
      "label": "PERCENT",
      "start": 738,
      "end": 743,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "$942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Fore",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Guggenheim",
      "label": "ORG",
      "start": 762,
      "end": 772,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "y rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Compan",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly and Company",
      "label": "ORG",
      "start": 802,
      "end": 823,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "otential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurgin",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 830,
      "end": 833,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand f",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Mounjaro",
      "label": "PRODUCT",
      "start": 904,
      "end": 912,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "e Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong qua",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Zepbound",
      "label": "ORG",
      "start": 917,
      "end": 925,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "Surging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 936,
      "end": 939,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nC",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "another strong quarter",
      "label": "DATE",
      "start": 944,
      "end": 966,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "oss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Dr",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Q2",
      "label": "DATE",
      "start": 976,
      "end": 978,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Mounjaro",
      "label": "ORG",
      "start": 992,
      "end": 1000,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "r another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Zepbound",
      "label": "PRODUCT",
      "start": 1005,
      "end": 1013,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "ong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPosit",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Another Strong Quarter",
      "label": "DATE",
      "start": 1020,
      "end": 1042,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "ad of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:\nThe FDA approv",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 1047,
      "end": 1056,
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "context": "aro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:\nThe FDA approved a safer, mo",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FDA",
      "label": "ORG",
      "start": 1082,
      "end": 1085,
      "sentence": "The FDA approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing safety concerns and broadening patient access.",
      "context": "ng Quarter for Eli Lilly?\nPositive Sentiment:\nThe FDA approved a safer, more gradual dosing label for K",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Kisunla",
      "label": "PRODUCT",
      "start": 1134,
      "end": 1141,
      "sentence": "The FDA approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing safety concerns and broadening patient access.",
      "context": "A approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing s",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly And Company",
      "label": "ORG",
      "start": 1237,
      "end": 1258,
      "sentence": "Eli Lilly And Company Stock:",
      "context": "ng safety concerns and broadening patient access.\nEli Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "U.S.",
      "label": "GPE",
      "start": 1266,
      "end": 1270,
      "sentence": "U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s\nPositive Sentiment:",
      "context": "ning patient access.\nEli Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For Early Alzhe",
      "is_company": false,
      "is_person": false,
      "is_location": true,
      "is_financial": false
    },
    {
      "text": "Kisunla",
      "label": "PRODUCT",
      "start": 1290,
      "end": 1297,
      "sentence": "U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s\nPositive Sentiment:",
      "context": "Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s\nPositive Sentiment:",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 1459,
      "end": 1468,
      "sentence": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "context": "s, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 1470,
      "end": 1473,
      "sentence": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "context": "ring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earni",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Seven",
      "label": "CARDINAL",
      "start": 1546,
      "end": 1551,
      "sentence": "Seven analysts offered a mixed expert outlook, with ratings ranging from Hold to Buy but no consensus shift.",
      "context": "Street Bull Ahead of Earnings\nNeutral Sentiment:\nSeven analysts offered a mixed expert outlook, with rat",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 1692,
      "end": 1701,
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "context": "ensus shift.\nA Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly f",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "7",
      "label": "CARDINAL",
      "start": 1710,
      "end": 1711,
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "context": "mpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 1740,
      "end": 1749,
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "context": "n Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity t",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "YouTube",
      "label": "ORG",
      "start": 1764,
      "end": 1771,
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "context": "alysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting i",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AVGO",
      "label": "ORG",
      "start": 1872,
      "end": 1876,
      "sentence": "AVGO, LLY, UBER\nNeutral Sentiment:",
      "context": "s role but offering no fresh catalyst.\nThe Big 3: AVGO, LLY, UBER\nNeutral Sentiment:\n“Famous Hoosiers” p",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 1878,
      "end": 1881,
      "sentence": "AVGO, LLY, UBER\nNeutral Sentiment:",
      "context": "but offering no fresh catalyst.\nThe Big 3: AVGO, LLY, UBER\nNeutral Sentiment:\n“Famous Hoosiers” progra",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Famous Hoosiers",
      "label": "ORG",
      "start": 1908,
      "end": 1923,
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "context": "t.\nThe Big 3: AVGO, LLY, UBER\nNeutral Sentiment:\n“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly’s",
      "label": "ORG",
      "start": 1948,
      "end": 1959,
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "context": "ntiment:\n“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility with",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Indiana",
      "label": "GPE",
      "start": 1960,
      "end": 1967,
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "context": "mous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without imme",
      "is_company": false,
      "is_person": false,
      "is_location": true,
      "is_financial": false
    },
    {
      "text": "Famous Hoosiers",
      "label": "ORG",
      "start": 2041,
      "end": 2056,
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "context": "ty visibility without immediate financial impact.\nFamous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly",
      "label": "ORG",
      "start": 2077,
      "end": 2087,
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "context": "ncial impact.\nFamous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:\nLLY released multiple Phase 3 p",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 2106,
      "end": 2109,
      "sentence": "LLY released multiple Phase 3 pipeline updates—from Remternetug drug delivery to EMBER-3 in breast cancer and several immunology and neurological studies—underscoring broad R&D activity.",
      "context": "program to focus on Eli Lilly\nNeutral Sentiment:\nLLY released multiple Phase 3 pipeline updates—from R",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly’s",
      "label": "ORG",
      "start": 2293,
      "end": 2304,
      "sentence": "Eli Lilly’s Remternetug Study: A Step Forward in Drug Delivery\nNegative Sentiment:",
      "context": "ological studies—underscoring broad R&D activity.\nEli Lilly’s Remternetug Study: A Step Forward in Drug Deliver",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Cantor Fitzgerald",
      "label": "ORG",
      "start": 2376,
      "end": 2393,
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "context": "Step Forward in Drug Delivery\nNegative Sentiment:\nCantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $2",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 2406,
      "end": 2412,
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "context": "Negative Sentiment:\nCantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling sli",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "21.76",
      "label": "MONEY",
      "start": 2430,
      "end": 2435,
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "context": "or Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "21.91",
      "label": "MONEY",
      "start": 2442,
      "end": 2447,
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "context": "d trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings gro",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "FY2025",
      "label": "DATE",
      "start": 2502,
      "end": 2508,
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "context": "naling slightly slower near-term earnings growth.\nFY2025 EPS Estimates for LLY Decreased by Cantor Fitzger",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 2527,
      "end": 2530,
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "context": "ar-term earnings growth.\nFY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Cantor Fitzgerald",
      "label": "ORG",
      "start": 2544,
      "end": 2561,
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "context": "growth.\nFY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:\nShares dipped around 1.3% as",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "around 1.3%",
      "label": "PERCENT",
      "start": 2596,
      "end": 2607,
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "context": "ntor Fitzgerald\nNegative Sentiment:\nShares dipped around 1.3% as broader market pressure weighed on LLY despite",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 2646,
      "end": 2649,
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "context": "around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.\nEli Lilly and Com",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "Eli Lilly and Company",
      "label": "ORG",
      "start": 2682,
      "end": 2703,
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "context": "re weighed on LLY despite positive pipeline news.\nEli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happene",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 2710,
      "end": 2713,
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "context": "sitive pipeline news.\nEli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1.3%",
      "label": "PERCENT",
      "start": 2727,
      "end": 2731,
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "context": "ews.\nEli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:\nOver t",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "the past year",
      "label": "DATE",
      "start": 2780,
      "end": 2793,
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "context": "% – Here's What Happened\nNegative Sentiment:\nOver the past year, LLY is down more than 15%, prompting debate on w",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "LLY",
      "label": "ORG",
      "start": 2795,
      "end": 2798,
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "context": "Happened\nNegative Sentiment:\nOver the past year, LLY is down more than 15%, prompting debate on whethe",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "more than 15%",
      "label": "PERCENT",
      "start": 2807,
      "end": 2820,
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "context": "gative Sentiment:\nOver the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sel",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "Lilly",
      "label": "ORG",
      "start": 2897,
      "end": 2902,
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "context": "er to buy, hold, or sell amid valuation concerns.\nLilly Down More Than 15% in a Year: Time to Buy, Sell o",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "More Than 15%",
      "label": "PERCENT",
      "start": 2908,
      "end": 2921,
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "context": "hold, or sell amid valuation concerns.\nLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?\nPosted 1+ d",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": true
    },
    {
      "text": "a Year",
      "label": "DATE",
      "start": 2925,
      "end": 2931,
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "context": "d valuation concerns.\nLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?\nPosted 1+ days ago\nAI",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "1+ days ago",
      "label": "DATE",
      "start": 2967,
      "end": 2978,
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "context": "15% in a Year: Time to Buy, Sell or Hold?\nPosted 1+ days ago\nAI Generated. May Contain Errors.",
      "is_company": false,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    },
    {
      "text": "AI",
      "label": "ORG",
      "start": 2979,
      "end": 2981,
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "context": "ar: Time to Buy, Sell or Hold?\nPosted 1+ days ago\nAI Generated. May Contain Errors.",
      "is_company": true,
      "is_person": false,
      "is_location": false,
      "is_financial": false
    }
  ],
  "relationships": [
    {
      "type": "SVO",
      "subject": "Drugs",
      "verb": "Drive",
      "object": "Growth",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "JPMorgan",
      "verb": "set",
      "object": "target",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "Stock",
      "verb": "Surges",
      "object": "Sentiment",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "JPMorgan",
      "verb": "Forecasts",
      "object": "Target",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "Guggenheim",
      "verb": "raised",
      "object": "objective",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "Guggenheim",
      "verb": "Issues",
      "object": "Forecast",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "Mounjaro",
      "verb": "Drive",
      "object": "Quarter",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance": 55
    },
    {
      "type": "SVO",
      "subject": "FDA",
      "verb": "approved",
      "object": "label",
      "sentence": "The FDA approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing safety concerns and broadening patient access.",
      "importance": 2
    },
    {
      "type": "SVO",
      "subject": "FDA",
      "verb": "Approves",
      "object": "Dosing",
      "sentence": "U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s\nPositive Sentiment:",
      "importance": 2
    },
    {
      "type": "SVO",
      "subject": "Lilly",
      "verb": "Attracts",
      "object": "Bull",
      "sentence": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "importance": 6
    },
    {
      "type": "SVO",
      "subject": "analysts",
      "verb": "offered",
      "object": "outlook",
      "sentence": "Seven analysts offered a mixed expert outlook, with ratings ranging from Hold to Buy but no consensus shift.",
      "importance": 4
    },
    {
      "type": "SVO",
      "subject": "program",
      "verb": "spotlight",
      "object": "roots",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "importance": 6
    },
    {
      "type": "SVO",
      "subject": "LLY",
      "verb": "released",
      "object": "updates",
      "sentence": "LLY released multiple Phase 3 pipeline updates—from Remternetug drug delivery to EMBER-3 in breast cancer and several immunology and neurological studies—underscoring broad R&D activity.",
      "importance": 2
    },
    {
      "type": "SVO",
      "subject": "Fitzgerald",
      "verb": "trimmed",
      "object": "estimate",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "importance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "today",
      "entity2_type": "DATE",
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "today",
      "entity2_type": "DATE",
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "today",
      "entity2_type": "DATE",
      "sentence": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "to",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 62
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 85
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 94
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 95
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 100
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 106
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 107
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 108
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 112
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 128
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 130
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 132
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 134
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 135
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 136
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 139
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 144
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 146
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 148
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 149
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 150
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 152
    },
    {
      "type": "co-occurrence",
      "entity1": "up",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 153
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 64
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 93
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 94
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 99
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 104
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 106
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 107
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 111
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 127
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 129
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 131
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 133
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 134
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 135
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 138
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 143
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 145
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 147
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 148
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 149
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 151
    },
    {
      "type": "co-occurrence",
      "entity1": "to",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 152
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 60
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 76
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 92
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 93
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 98
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 103
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 104
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 106
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 110
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 126
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 128
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 130
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 132
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 133
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 134
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 137
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 142
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 144
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 146
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 147
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 148
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 150
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 151
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 62
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 92
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 97
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 102
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 103
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 104
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 109
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 125
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 127
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 129
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 131
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 132
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 133
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 136
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 141
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 143
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 145
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 146
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 147
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 149
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 150
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 62
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 69
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 79
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 89
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 90
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 92
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 96
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 112
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 114
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 116
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 118
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 119
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 120
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 123
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 128
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 130
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 132
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 133
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 134
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 136
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 137
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "300",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 89
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 90
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 95
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 111
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 113
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 115
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 117
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 118
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 119
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 122
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 127
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 129
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 131
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 132
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 133
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 135
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 136
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 62
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 72
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 85
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 89
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 107
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 109
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 111
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 112
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 113
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 116
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 121
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 123
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 125
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 126
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 127
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 129
    },
    {
      "type": "co-occurrence",
      "entity1": "300",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 130
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 76
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 81
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 104
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 106
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 108
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 110
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 111
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 112
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 115
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 120
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 122
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 124
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 125
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 126
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 128
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 129
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 53
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 62
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 73
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 74
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 76
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 80
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 96
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 98
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 100
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 102
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 103
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 104
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 107
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 112
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 114
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 116
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 117
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 118
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 120
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 121
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 69
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 93
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 95
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 97
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 98
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 99
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 102
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 107
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 109
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 111
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 112
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 113
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 115
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 116
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "decade",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 53
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 60
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 81
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 85
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 87
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 89
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 92
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 97
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 99
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 101
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 102
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 103
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 106
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 52
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 60
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 64
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 80
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 86
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 87
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 96
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 98
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 100
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 101
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 102
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 104
    },
    {
      "type": "co-occurrence",
      "entity1": "decade",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 105
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 51
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 73
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 79
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 87
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 89
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 92
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 93
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 95
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 96
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "JPMorgan",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 72
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 74
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 76
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 78
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 81
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 86
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 90
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 92
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 94
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 95
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "1,100",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 66
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 72
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 73
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 74
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 77
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 82
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 86
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 87
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 90
    },
    {
      "type": "co-occurrence",
      "entity1": "JPMorgan",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 91
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 67
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 69
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 74
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 79
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 81
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 83
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 84
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 85
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 87
    },
    {
      "type": "co-occurrence",
      "entity1": "1,100",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 88
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "942",
      "entity2_type": "MONEY",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 52
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 66
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 70
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 71
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 72
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 74
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 75
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "18.7",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 51
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 61
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 63
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 64
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 65
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 67
    },
    {
      "type": "co-occurrence",
      "entity1": "942",
      "entity1_type": "MONEY",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 68
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 52
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 56
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "18.7",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 59
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Guggenheim",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 51
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 53
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 54
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 55
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 57
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 58
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 35
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 49
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 50
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 52
    },
    {
      "type": "co-occurrence",
      "entity1": "Guggenheim",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 53
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 48
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 30
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 33
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 47
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 29
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 39
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 43
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 46
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 26
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 28
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 31
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 42
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 44
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 45
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 27
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 32
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 34
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 36
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 37
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 38
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 40
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 41
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Zepbound",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 24
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "PRODUCT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 25
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 22
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 23
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 20
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 21
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "another",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 19
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "strong",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 18
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Q2",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 16
    },
    {
      "type": "co-occurrence",
      "entity1": "quarter",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 17
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Mounjaro",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 13
    },
    {
      "type": "co-occurrence",
      "entity1": "Q2",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "ORG",
      "entity2": "Zepbound",
      "entity2_type": "PRODUCT",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "ORG",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "ORG",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "ORG",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Mounjaro",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "PRODUCT",
      "entity2": "Another",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "PRODUCT",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "PRODUCT",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "PRODUCT",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Zepbound",
      "entity1_type": "PRODUCT",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Another",
      "entity1_type": "DATE",
      "entity2": "Strong",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Another",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Another",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Another",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Strong",
      "entity1_type": "DATE",
      "entity2": "Quarter",
      "entity2_type": "DATE",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Strong",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Strong",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Quarter",
      "entity1_type": "DATE",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Quarter",
      "entity1_type": "DATE",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "FDA",
      "entity1_type": "ORG",
      "entity2": "Kisunla",
      "entity2_type": "PRODUCT",
      "sentence": "The FDA approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing safety concerns and broadening patient access.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly And Company Stock:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "And",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly And Company Stock:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly And Company Stock:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "And",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly And Company Stock:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly And Company Stock:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "And",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly And Company Stock:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "U.S.",
      "entity1_type": "GPE",
      "entity2": "Kisunla",
      "entity2_type": "PRODUCT",
      "sentence": "U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s\nPositive Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "7",
      "entity2_type": "CARDINAL",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "YouTube",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 15
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "7",
      "entity2_type": "CARDINAL",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "YouTube",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 14
    },
    {
      "type": "co-occurrence",
      "entity1": "7",
      "entity1_type": "CARDINAL",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "7",
      "entity1_type": "CARDINAL",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "7",
      "entity1_type": "CARDINAL",
      "entity2": "YouTube",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "YouTube",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "YouTube",
      "entity2_type": "ORG",
      "sentence": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "AVGO",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "AVGO, LLY, UBER\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Hoosiers",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Indiana",
      "entity2_type": "GPE",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "Indiana",
      "entity2_type": "GPE",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Indiana",
      "entity2_type": "GPE",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Indiana",
      "entity2_type": "GPE",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "’s",
      "entity1_type": "ORG",
      "entity2": "Indiana",
      "entity2_type": "GPE",
      "sentence": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Hoosiers",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Famous",
      "entity1_type": "ORG",
      "entity2": "\n",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "Eli",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Hoosiers",
      "entity1_type": "ORG",
      "entity2": "\n",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "\n",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "\n",
      "entity2_type": "ORG",
      "sentence": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly’s Remternetug Study: A Step Forward in Drug Delivery\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly’s Remternetug Study: A Step Forward in Drug Delivery\nNegative Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "’s",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly’s Remternetug Study: A Step Forward in Drug Delivery\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "21.76",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "21.91",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "FY2025",
      "entity2_type": "DATE",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "21.76",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Fitzgerald",
      "entity1_type": "ORG",
      "entity2": "21.91",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "21.76",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "21.91",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "21.76",
      "entity1_type": "MONEY",
      "entity2": "21.91",
      "entity2_type": "MONEY",
      "sentence": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Cantor",
      "entity2_type": "ORG",
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "FY2025",
      "entity1_type": "DATE",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Cantor",
      "entity2_type": "ORG",
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Cantor",
      "entity1_type": "ORG",
      "entity2": "Fitzgerald",
      "entity2_type": "ORG",
      "sentence": "FY2025 EPS Estimates for LLY Decreased by Cantor Fitzgerald\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "around",
      "entity1_type": "PERCENT",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "around",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "around",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "1.3",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1.3",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Shares dipped around 1.3% as broader market pressure weighed on LLY despite positive pipeline news.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Lilly",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "Eli",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 12
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "and",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 11
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "Company",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "and",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "Company",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "1.3",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "1.3",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "past",
      "entity2_type": "DATE",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "more",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "than",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "the",
      "entity1_type": "DATE",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 10
    },
    {
      "type": "co-occurrence",
      "entity1": "past",
      "entity1_type": "DATE",
      "entity2": "year",
      "entity2_type": "DATE",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "past",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "past",
      "entity1_type": "DATE",
      "entity2": "more",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "past",
      "entity1_type": "DATE",
      "entity2": "than",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "past",
      "entity1_type": "DATE",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "past",
      "entity1_type": "DATE",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 9
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "LLY",
      "entity2_type": "ORG",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "more",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "than",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "year",
      "entity1_type": "DATE",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "more",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "than",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "LLY",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "more",
      "entity1_type": "PERCENT",
      "entity2": "than",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "more",
      "entity1_type": "PERCENT",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "more",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "than",
      "entity1_type": "PERCENT",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "than",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "15",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "More",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Than",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 7
    },
    {
      "type": "co-occurrence",
      "entity1": "Lilly",
      "entity1_type": "ORG",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 8
    },
    {
      "type": "co-occurrence",
      "entity1": "More",
      "entity1_type": "PERCENT",
      "entity2": "Than",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "More",
      "entity1_type": "PERCENT",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "More",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "More",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "More",
      "entity1_type": "PERCENT",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 6
    },
    {
      "type": "co-occurrence",
      "entity1": "Than",
      "entity1_type": "PERCENT",
      "entity2": "15",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "Than",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "Than",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "Than",
      "entity1_type": "PERCENT",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "15",
      "entity1_type": "PERCENT",
      "entity2": "%",
      "entity2_type": "PERCENT",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "15",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "15",
      "entity1_type": "PERCENT",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "a",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "%",
      "entity1_type": "PERCENT",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "a",
      "entity1_type": "DATE",
      "entity2": "Year",
      "entity2_type": "DATE",
      "sentence": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "+",
      "entity2_type": "DATE",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "1",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 5
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "days",
      "entity2_type": "DATE",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 2
    },
    {
      "type": "co-occurrence",
      "entity1": "+",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 4
    },
    {
      "type": "co-occurrence",
      "entity1": "days",
      "entity1_type": "DATE",
      "entity2": "ago",
      "entity2_type": "DATE",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 1
    },
    {
      "type": "co-occurrence",
      "entity1": "days",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 3
    },
    {
      "type": "co-occurrence",
      "entity1": "ago",
      "entity1_type": "DATE",
      "entity2": "AI",
      "entity2_type": "ORG",
      "sentence": "Posted 1+ days ago\nAI Generated.",
      "distance": 2
    }
  ],
  "key_phrases": [
    {
      "text": "a mix",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "bullish research",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "pipeline updates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "analyst revisions",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the key drivers",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the stock’s performance",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Wall Street",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "several late-stage drug candidates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "up to 300% EPS growth",
      "type": "noun_chunk",
      "category": "trend"
    },
    {
      "text": "upcoming launches",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Wall Street",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "New Drugs",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "300% EPS Growth",
      "type": "noun_chunk",
      "category": "trend"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a lofty $1,100 price target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Buy rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a decade",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "blockbuster therapies",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly Stock",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "$1,100 Price Target",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its price objective",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Buy rating",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "an 18.7% upside potential",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Forecast",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Surging demand",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "weight-loss drugs",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "another strong quarter",
      "type": "noun_chunk",
      "category": "temporal"
    },
    {
      "text": "Q2 results",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Another Strong Quarter",
      "type": "noun_chunk",
      "category": "temporal"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "The FDA",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a safer, more gradual dosing label",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "early Alzheimer",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "safety concerns",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "patient access",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "U.S. FDA",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Safer Kisunla Dosing",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Early Alzheimer",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Positive Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Another Wall Street strategist",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "growing institutional confidence",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Another Wall Street Bull",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Seven analysts",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a mixed expert outlook",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "no consensus shift",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "A Glimpse",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "The Expert Outlook",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "7 Analysts",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a YouTube segment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "market “vanity trades",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "its role",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "no fresh catalyst",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "The Big",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "“Famous Hoosiers” program",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly’s Indiana roots",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "community visibility",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "immediate financial impact",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Famous Hoosiers program",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Neutral Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "multiple Phase 3 pipeline updates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Remternetug drug delivery",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "breast cancer",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "several immunology and neurological studies",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "broad R&D activity",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Eli Lilly’s Remternetug Study",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "A Step",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Drug Delivery",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Cantor Fitzgerald",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "its FY2025 EPS estimate",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "slightly slower near-term earnings growth",
      "type": "noun_chunk",
      "category": "financial_metric"
    },
    {
      "text": "FY2025 EPS Estimates",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Cantor Fitzgerald",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "broader market pressure",
      "type": "noun_chunk",
      "category": "market_term"
    },
    {
      "text": "positive pipeline news",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "Negative Sentiment",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "the past year",
      "type": "noun_chunk",
      "category": "temporal"
    },
    {
      "text": "valuation concerns",
      "type": "noun_chunk",
      "category": "general"
    },
    {
      "text": "a Year",
      "type": "noun_chunk",
      "category": "temporal"
    },
    {
      "text": "$1,100",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$1,100",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$942",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$21.76",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "$21.91",
      "type": "pattern",
      "category": "money"
    },
    {
      "text": "300%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "300%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "18.7%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "1.3%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "1.3%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "15%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "15%",
      "type": "pattern",
      "category": "percentage"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "FY2025",
      "type": "pattern",
      "category": "fiscal_year"
    },
    {
      "text": "growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "loss",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "Earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "earnings",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "growth",
      "type": "pattern",
      "category": "financial_metric"
    },
    {
      "text": "stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "Stock",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "market",
      "type": "pattern",
      "category": "market_term"
    },
    {
      "text": "market",
      "type": "pattern",
      "category": "market_term"
    }
  ],
  "important_sentences": [
    {
      "text": "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "importance_score": 188,
      "entity_count": 40,
      "financial_keyword_count": 15,
      "money_count": 3,
      "company_count": 12,
      "sentiment": "positive"
    },
    {
      "text": "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth.",
      "importance_score": 33,
      "entity_count": 5,
      "financial_keyword_count": 3,
      "money_count": 2,
      "company_count": 1,
      "sentiment": "positive"
    },
    {
      "text": "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns.",
      "importance_score": 32,
      "entity_count": 8,
      "financial_keyword_count": 4,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "neutral"
    },
    {
      "text": "A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts\nNeutral Sentiment:\nEli Lilly featured in a YouTube segment on market “vanity trades,” highlighting its role but offering no fresh catalyst.",
      "importance_score": 30,
      "entity_count": 6,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 3,
      "sentiment": "neutral"
    },
    {
      "text": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "importance_score": 27,
      "entity_count": 7,
      "financial_keyword_count": 3,
      "money_count": 0,
      "company_count": 1,
      "sentiment": "neutral"
    },
    {
      "text": "Another Wall Street strategist turned bullish ahead of earnings, underscoring growing institutional confidence.\nEli Lilly (LLY) Attracts Another Wall Street Bull Ahead of Earnings\nNeutral Sentiment:",
      "importance_score": 23,
      "entity_count": 3,
      "financial_keyword_count": 3,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Eli Lilly and Company (LLY) shares moved today on a mix of bullish research, pipeline updates, and analyst revisions.",
      "importance_score": 22,
      "entity_count": 4,
      "financial_keyword_count": 2,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – Here's What Happened\nNegative Sentiment:",
      "importance_score": 22,
      "entity_count": 7,
      "financial_keyword_count": 0,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "negative"
    },
    {
      "text": "“Famous Hoosiers” program will spotlight Eli Lilly’s Indiana roots, boosting community visibility without immediate financial impact.",
      "importance_score": 20,
      "entity_count": 6,
      "financial_keyword_count": 0,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    },
    {
      "text": "Famous Hoosiers program to focus on Eli Lilly\nNeutral Sentiment:",
      "importance_score": 18,
      "entity_count": 5,
      "financial_keyword_count": 0,
      "money_count": 0,
      "company_count": 2,
      "sentiment": "neutral"
    }
  ],
  "entity_statistics": {
    "total_entities": 68,
    "unique_entities": 42,
    "type_counts": {
      "ORG": 38,
      "DATE": 10,
      "PERCENT": 7,
      "MONEY": 5,
      "PRODUCT": 4,
      "GPE": 2,
      "CARDINAL": 2
    },
    "type_distribution": {
      "ORG": 0.5588235294117647,
      "DATE": 0.14705882352941177,
      "PERCENT": 0.10294117647058823,
      "MONEY": 0.07352941176470588,
      "PRODUCT": 0.058823529411764705,
      "GPE": 0.029411764705882353,
      "CARDINAL": 0.029411764705882353
    },
    "most_common_entities": [
      [
        "LLY",
        10
      ],
      [
        "Eli Lilly",
        7
      ],
      [
        "JPMorgan",
        2
      ],
      [
        "1,100",
        2
      ],
      [
        "Guggenheim",
        2
      ],
      [
        "Eli Lilly and Company",
        2
      ],
      [
        "Mounjaro",
        2
      ],
      [
        "Zepbound",
        2
      ],
      [
        "Kisunla",
        2
      ],
      [
        "Famous Hoosiers",
        2
      ]
    ],
    "entity_types_found": [
      "ORG",
      "DATE",
      "PERCENT",
      "MONEY",
      "PRODUCT",
      "GPE",
      "CARDINAL"
    ],
    "company_entities": 38,
    "person_entities": 0,
    "financial_entities": 12,
    "entity_density": 0.1559633027522936
  },
  "financial_analysis": {
    "money_amounts": [
      "1,100",
      "1,100",
      "942",
      "21.76",
      "21.91"
    ],
    "percentages": [
      "up to 300%",
      "300%",
      "18.7%",
      "around 1.3%",
      "1.3%",
      "more than 15%",
      "More Than 15%"
    ],
    "companies": [
      "Eli Lilly",
      "LLY",
      "Eli Lilly",
      "JPMorgan",
      "Eli Lilly",
      "JPMorgan",
      "Guggenheim",
      "Guggenheim",
      "Eli Lilly and Company",
      "LLY",
      "Zepbound",
      "LLY",
      "Mounjaro",
      "Eli Lilly",
      "FDA",
      "Eli Lilly And Company",
      "Eli Lilly",
      "LLY",
      "Eli Lilly",
      "Eli Lilly",
      "YouTube",
      "AVGO",
      "LLY",
      "Famous Hoosiers",
      "Eli Lilly’s",
      "Famous Hoosiers",
      "Eli Lilly\n",
      "LLY",
      "Eli Lilly’s",
      "Cantor Fitzgerald",
      "LLY",
      "Cantor Fitzgerald",
      "LLY",
      "Eli Lilly and Company",
      "LLY",
      "LLY",
      "Lilly",
      "AI"
    ],
    "people": [],
    "dates": [
      "today",
      "a decade",
      "another strong quarter",
      "Q2",
      "Another Strong Quarter",
      "FY2025",
      "FY2025",
      "the past year",
      "a Year",
      "1+ days ago"
    ],
    "financial_terms": [
      "Earnings",
      "Stock",
      "earnings",
      "Quarter",
      "growth",
      "Growth",
      "quarter",
      "market",
      "loss",
      "stock"
    ],
    "financial_metrics": [],
    "market_indicators": [
      "Price",
      "price",
      "target",
      "rating",
      "Bull",
      "Target"
    ]
  },
  "temporal_analysis": {
    "dates": [
      "today",
      "a decade",
      "another strong quarter",
      "Q2",
      "Another Strong Quarter",
      "FY2025",
      "FY2025",
      "the past year",
      "a Year",
      "1+ days ago"
    ],
    "time_expressions": [],
    "temporal_relationships": [
      "upcoming",
      "past",
      "today"
    ],
    "quarters": [
      "Q2",
      "Another Strong Quarter"
    ],
    "years": [],
    "time_periods": []
  },
  "sentiment_analysis": {
    "positive_words": 19,
    "negative_words": 7,
    "positive_ratio": 0.04357798165137615,
    "negative_ratio": 0.016055045871559634,
    "sentiment_score": 0.027522935779816515,
    "sentiment_label": "positive",
    "sentiment_strength": 0.027522935779816515,
    "confidence": 0.27522935779816515
  },
  "industry_analysis": {
    "dominant_industry": "healthcare",
    "industry_scores": {
      "tech": 1,
      "finance": 0,
      "healthcare": 3,
      "energy": 0,
      "retail": 0,
      "automotive": 2,
      "media": 1,
      "industrial": 0,
      "real_estate": 0,
      "telecom": 0,
      "food_beverage": 0,
      "travel": 0,
      "education": 0,
      "professional": 0,
      "mining": 0,
      "aerospace": 0,
      "environmental": 0,
      "cannabis": 0
    },
    "confidence": 0.42857142857142855
  },
  "market_analysis": {
    "market_sentiment": "bullish",
    "bullish_indicators": 2,
    "bearish_indicators": 1,
    "market_conditions": {
      "volatility": "normal",
      "volume": "normal",
      "trend": "bullish"
    },
    "trading_activity": "normal"
  },
  "competitor_analysis": {
    "companies_mentioned": [
      "Eli Lilly",
      "LLY",
      "Eli Lilly",
      "JPMorgan",
      "Eli Lilly",
      "JPMorgan",
      "Guggenheim",
      "Guggenheim",
      "Eli Lilly and Company",
      "LLY",
      "Zepbound",
      "LLY",
      "Mounjaro",
      "Eli Lilly",
      "FDA",
      "Eli Lilly And Company",
      "Eli Lilly",
      "LLY",
      "Eli Lilly",
      "Eli Lilly",
      "YouTube",
      "AVGO",
      "LLY",
      "Famous Hoosiers",
      "Eli Lilly’s",
      "Famous Hoosiers",
      "Eli Lilly\n",
      "LLY",
      "Eli Lilly’s",
      "Cantor Fitzgerald",
      "LLY",
      "Cantor Fitzgerald",
      "LLY",
      "Eli Lilly and Company",
      "LLY",
      "LLY",
      "Lilly",
      "AI"
    ],
    "competitive_context": [],
    "competitor_count": 38,
    "has_competitive_language": false
  },
  "risk_analysis": {
    "risk_sentences": [
      "The FDA approved a safer, more gradual dosing label for Kisunla (donanemab-azbt) in early Alzheimer’s, reducing safety concerns and broadening patient access.",
      "Over the past year, LLY is down more than 15%, prompting debate on whether to buy, hold, or sell amid valuation concerns."
    ],
    "risk_count": 2,
    "risk_level": "medium"
  },
  "opportunity_analysis": {
    "opportunity_sentences": [
      "Positive Sentiment:\nWall Street is bullish on several late-stage drug candidates, projecting up to 300% EPS growth from upcoming launches.\nWall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth\nPositive Sentiment:\nJPMorgan set a lofty $1,100 price target and reiterated a Buy rating, citing a decade of growth fueled by blockbuster therapies.\nEli Lilly Stock Surges as JPMorgan Forecasts $1,100 Price Target and Sees Decade of Growth\nPositive Sentiment:\nGuggenheim raised its price objective to $942 and maintained a Buy rating, highlighting an 18.7% upside potential.\nGuggenheim Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price\nPositive Sentiment:\nSurging demand for weight-loss drugs Mounjaro and Zepbound positions LLY for another strong quarter ahead of Q2 results.\nCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?\nPositive Sentiment:",
      "Cantor Fitzgerald trimmed its FY2025 EPS estimate to $21.76 from $21.91, signaling slightly slower near-term earnings growth."
    ],
    "opportunity_count": 2,
    "opportunity_level": "medium"
  },
  "processing_metadata": {
    "timestamp": "2025-07-13T05:34:34.993671",
    "model_used": "en_core_web_trf",
    "text_length": 3012
  }
}